The effects of oral dipyridamole treatment on the innate immune response during human endotoxemia.

Completed

Conditions: Blood poisoning
sepsis
10004018
10011954

Registration Number: NL-OMON34679

Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 30

Inclusion Criteria

Age >= 18 and <= 35 years
Male
Healthy

Exclusion Criteria

Use of any medication.
History of allergic reaction to dipyridamole
Bleeding disorder.
Smoking.
Previous spontaneous vagal collapse.
History, signs or symptoms of cardiovascular disease.
Cardiac conduction abnormalities on the ECG consisting of a 2nd degree atrioventricular block or a complex bundle branch block.
Hypertension (defined as RR systolic > 160 or RR diastolic > 90).
Hypotension (defined as RR systolic < 100 or RR diastolic < 50).
Renal impairment (defined as plasma creatinin >120 µmol/l).
Liver enzyme abnormalities or positive hepatitis serology.
Positive HIV serology or any other obvious disease associated with immune deficiency.
Febrile illness in the week before the LPS challenge.
Participation in a drug trial or donation of blood 3 months prior to the LPS challenge.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study parameter is the concentration of circulating cytokines<br /><br>following LPS administration in the absence or presence of dipyridamole. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary study parameters include endothelial dysfunction, vascular<br /><br>reactivity, subclinical renal injury and the endogenous adenosine concentration<br /><br>after LPS administration in the absence or presence of dipyridamole. </p><br>